Entellus Medical (NASDAQ:ENTL) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Thursday.

Several other research analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Entellus Medical from a “buy” rating to a “hold” rating in a report on Tuesday, October 31st. Canaccord Genuity reissued a “hold” rating and issued a $17.00 price target on shares of Entellus Medical in a report on Tuesday, October 17th. BidaskClub raised shares of Entellus Medical from a “hold” rating to a “buy” rating in a report on Saturday, August 19th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $21.00 price target on shares of Entellus Medical in a report on Tuesday, August 22nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the stock. Entellus Medical has a consensus rating of “Hold” and an average target price of $20.40.

Shares of Entellus Medical (ENTL) traded up $0.36 during trading hours on Thursday, reaching $24.35. 1,716,074 shares of the company’s stock traded hands, compared to its average volume of 584,499. The company has a quick ratio of 1.71, a current ratio of 1.92 and a debt-to-equity ratio of 0.32. Entellus Medical has a 1 year low of $11.47 and a 1 year high of $24.40.

In other news, Director Brian E. Farley sold 101,319 shares of Entellus Medical stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $23.85, for a total transaction of $2,416,458.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Timothy B. Petrick sold 2,000 shares of Entellus Medical stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $18.00, for a total transaction of $36,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 193,469 shares of company stock valued at $4,157,111 over the last ninety days. 7.70% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Kopp Investment Advisors LLC lifted its holdings in shares of Entellus Medical by 0.5% during the 2nd quarter. Kopp Investment Advisors LLC now owns 11,874 shares of the medical technology company’s stock worth $197,000 after acquiring an additional 55 shares during the last quarter. First Mercantile Trust Co. lifted its holdings in shares of Entellus Medical by 45.3% during the 2nd quarter. First Mercantile Trust Co. now owns 8,206 shares of the medical technology company’s stock worth $136,000 after acquiring an additional 2,557 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Entellus Medical by 53.8% during the 1st quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock worth $102,000 after acquiring an additional 2,594 shares during the last quarter. Nationwide Fund Advisors lifted its holdings in shares of Entellus Medical by 61.7% during the 2nd quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock worth $114,000 after acquiring an additional 2,635 shares during the last quarter. Finally, Keybank National Association OH lifted its holdings in shares of Entellus Medical by 11.0% during the 2nd quarter. Keybank National Association OH now owns 32,594 shares of the medical technology company’s stock worth $540,000 after acquiring an additional 3,235 shares during the last quarter. 78.76% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Entellus Medical (ENTL) Upgraded to Hold by ValuEngine” was reported by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/09/entellus-medical-entl-upgraded-to-hold-by-valuengine.html.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.